InterCure reports NIS 130 million revenue and positive operating cash flow for first half 2025
I'm PortAI, I can summarize articles.
InterCure Ltd. reported NIS 130 million in revenue for H1 2025, with an Adjusted EBITDA of NIS 12.6 million, marking the eleventh consecutive half of positive EBITDA. The company generated positive cash flow from operations of NIS 12 million, a significant improvement from a negative cash flow of NIS 43 million in the previous year. Cash on hand increased to NIS 54 million, and shareholders’ equity reached NIS 432 million. InterCure also received NIS 81 million in compensation for war-related damages and entered a share purchase agreement to acquire Botanico Ltd.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments